earticle

영어

Neuropathic pain is a chronic disabling condition caused by different pathogenic mechanisms and seriously affects patient’s quality of life. Gabapentinoids, including pregabalin and gabapentin, have been recommended as one of the first-line drugs for the treatment of neuropathic pain. However, optimal dosing of these medications has been limited by adverse events such as dizziness, somnolence, peripheral edema and weight gain. Mirogabalin, a new generation ligand for the α2-δ subunits of voltage-gated calcium channels, provides long-lasting analgesic effects and a wider safety margin for adverse drug reactions due to the characteristic binding and dissociation kinetics for the α2δ-1 and α2δ-2 subunits. This article introduces the action mechanism, pharmacokinetics, clinical application, and reported clinical trials of mirogabalin for treating neuropathic pain.